Cargando…
Construction of tandem diabody (IL-6/CD20)-secreting human umbilical cord mesenchymal stem cells and its experimental treatment on diffuse large B cell lymphoma
BACKGROUND: More than 40% patients with diffuse large B cell lymphoma (DLBCL) experienced relapse or refractory (R/R) lymphoma after the standard first R-CHOP therapy. IL-6 was reportedly associated with chemotherapy resistance of rituximab. Further, mesenchymal stem cells (MSCs) are known as the po...
Autores principales: | Zhang, Jiayi, Zhong, Minglu, Zhong, Weijie, Lan, Yanfei, Yuan, Zhaohu, Duan, Yuyou, Wei, Yaming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476312/ https://www.ncbi.nlm.nih.gov/pubmed/36104733 http://dx.doi.org/10.1186/s13287-022-03169-4 |
Ejemplares similares
-
Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity
por: Mølgaard, K, et al.
Publicado: (2017) -
Construction of a disulfide‐stabilized diabody against fibroblast growth factor‐2 and the inhibition activity in targeting breast cancer
por: Cai, Yaxiong, et al.
Publicado: (2016) -
Fermentation, Purification, and Tumor Inhibition of a Disulfide-Stabilized Diabody Against Fibroblast Growth Factor-2
por: Zhang, Simin, et al.
Publicado: (2021) -
Inhibition activity of a disulfide-stabilized diabody against basic fibroblast growth factor in lung cancer
por: Cai, Yaxiong, et al.
Publicado: (2017) -
Human bone marrow-derived mesenchymal stem cells promote the growth and drug-resistance of diffuse large B-cell lymphoma by secreting IL-6 and elevating IL-17A levels
por: Zhong, Weijie, et al.
Publicado: (2019)